News >

Consolidation Approach Extends PFS in Multiple Myeloma

Jason Harris
Published: Wednesday, Apr 19, 2017

Michel Attal, MD

Michel Attal, MD

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD), when used in conjunction with stem cell transplantation, extended progression-free survival (PFS) compared with RVD alone in patients with multiple myeloma.1 However, in results from Intergroupe Francophone du Myélome (IFM) 2009 trial published in New England Journal of Medicine, researchers found that overall survival (OS) was similar for both treatments.

After the induction phase, all the patients underwent stem-cell mobilization with cyclophosphamide and granulocyte colony-stimulating factor.

During the consolidation phase, patients were randomly assigned to 5 cycles of RVD with a reduced daily dose of 10 mg of dexamethasone (n = 350) or 200 mg/m2 of IV melphalan plus autologous stem-cell transplantation (ASCT) followed by 2 cycles of RVD with 10 mg of dexamethasone (n = 350).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication